长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破

智通财经09-22 09:30

【长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破】智通财经APP获悉，近日，长风药业(02652.HK)宣布，其全球首创(First-in-Class)用于治疗间质性肺疾病(ILD)的吸入粉雾剂ICF004(化学药1类)的I期临床试验，已顺利完成首例健康志愿者的入组与给药工作。该项目是长风药业与上海交通大学医学院附属瑞金医院合作研发的科研成果，该候选药物正式迈入人体临床验证新阶段。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669528192?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-22 09:30","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2669528192","market":"hk","top_or_hot":-1,"title":"长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破】</b>智通财经APP获悉，近日，长风药业(02652.HK)宣布，其全球首创(First-in-Class)用于治疗间质性肺疾病(ILD)的吸入粉雾剂ICF004(化学药1类)的I期临床试验，已顺利完成首例健康志愿者的入组与给药工作。该项目是长风药业与上海交通大学医学院附属瑞金医院合作研发的科研成果，该候选药物正式迈入人体临床验证新阶段。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破】</b>智通财经APP获悉，近日，长风药业(02652.HK)宣布，其全球首创(First-in-Class)用于治疗间质性肺疾病(ILD)的吸入粉雾剂ICF004(化学药1类)的I期临床试验，已顺利完成首例健康志愿者的入组与给药工作。该项目是长风药业与上海交通大学医学院附属瑞金医院合作研发的科研成果，该候选药物正式迈入人体临床验证新阶段。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2669528192","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669528192","pubTimestamp":1790040640,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破】智通财经APP获悉，近日，长风药业(02652.HK)宣布，其全球首","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02652":"长风药业","BK1191":"制药"},"translate_title":"Changfeng Pharmaceutical (02652.HK) successfully completed the enrollment and administration of its world's first inhaled new drug, ICF004, in its first Phase I clinical trial in healthy volunteers. This collaborative innovation between industry, academia, and research accelerates breakthroughs in local original research.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1.5},"content_text":"【长风药业(02652.HK)全球首创吸入新药ICF004顺利完成I期临床首例健康志愿者入组给药，产学研协同创新，加速本土原研突破】智通财经APP获悉，近日，长风药业(02652.HK)宣布，其全球首创(First-in-Class)用于治疗间质性肺疾病(ILD)的吸入粉雾剂ICF004(化学药1类)的I期临床试验，已顺利完成首例健康志愿者的入组与给药工作。该项目是长风药业与上海交通大学医学院附属瑞金医院合作研发的科研成果，该候选药物正式迈入人体临床验证新阶段。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669528192","isCrawlerRequest":true}